search
Back to results

Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

Primary Purpose

Post-operative Pain

Status
Terminated
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Arcoxia®120 mg
P Tablet White Lichtenstein
Sponsored by
Claudia Spies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-operative Pain focused on measuring fast-track, colon or rectal surgery, pain relief

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • aged 18 or over
  • written informed consent
  • no inclusion in other medical studies according to the AMG (German drug law) during the study period
  • realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter

Exclusion Criteria:

  • ASA status IV-V
  • allergy against etoricoxib, other components or other NSAID
  • coronary heart disease
  • heart insufficiency NYHA II-IV
  • cerebrovascular disease
  • peripheral arterial occlusive disease
  • untreated arterial hypertonus
  • active peptic ulcera or active gastrointestinal bleeding
  • minor to severe liver dysfunction (beginning from Child - Plugh - Classification A)
  • kidney insufficiency
  • inflammatory bowel disease
  • pregnancy (positive hCG laboratory test) or lactation
  • Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index < 1 during study participation and for at least 3 consecutive months after study inclusion.
  • placement in an institution on order of an official authority
  • missing consent for saving and passing on pseudonymous data
  • hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption
  • no correct epidural catheter placement within 48 h after surgery

Sites / Locations

  • St. Hedwig Kliniken Berlin GmbH, Department of Anesthesiology and Intensive Care Medicine
  • Department of Anesthesiology, Sana-Klinikum Lichtenberg, Oskar-Ziethen-Krankenhaus
  • Department of Anesthesiology and Intensive Care Medicine, Campus Virchow Klinikum/Campus Charité Mitte, Charité Universitätsmedizin
  • Department of Anesthesiology, Johannes Wesling Klinikum Minden Mühlenkreiskliniken (AöR)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arcoxia® 120 mg

Sugar pill

Arm Description

Outcomes

Primary Outcome Measures

Primary end point of the study is the average pain level (scale 0-10) in the area of surgery during movement (walking a fixed number of steps) under active epidural analgesia, at the third day following laparoscopic colon or rectal surgery.
To demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement at the third day after laparoscopic colon or rectal surgery in the fast-track design.

Secondary Outcome Measures

Post-operative pain level during movement in the first 2 days after laparoscopic colon or rectal surgery.
Post-operative pain level during rest in the first 2 days after laparoscopic colon or rectal surgery.
Post-operative pain level during rest and movement from the third (one day after epidural catheter removal) until the fifth day after laparoscopic colon or rectal surgery
Incidence of pain events and the average pain intensity in body parts outside of the area of operations.
Incidence of new organ dysfunctions
Organ dysfunctions (cardiovascular, gastrointestinal, renal, respiratory, cognitive, infective)
Postoperative LOS
Patients level of satisfaction
Incidence of side effects
Side effects by IMP
Postoperative intensive care unit stay
Amount and frequency of intake of rescue medication

Full Information

First Posted
December 13, 2010
Last Updated
May 22, 2014
Sponsor
Claudia Spies
search

1. Study Identification

Unique Protocol Identification Number
NCT01259830
Brief Title
Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery
Official Title
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Terminated
Study Start Date
March 2011 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Claudia Spies

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Post-operative pain after laparoscopic colon and rectal surgery in fast-track design. A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Optimized pain relief is a core component of any fast-track regimen. In this context epidural analgesia has become the standard of care for early postoperative pain therapy. However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. The purpose of this study is to demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement after laparoscopic colon surgery in the fast-track design.
Detailed Description
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001). However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal. Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-operative Pain
Keywords
fast-track, colon or rectal surgery, pain relief

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arcoxia® 120 mg
Arm Type
Experimental
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Arcoxia®120 mg
Other Intervention Name(s)
Etoricoxib
Intervention Description
Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Intervention Type
Drug
Intervention Name(s)
P Tablet White Lichtenstein
Intervention Description
P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
Primary Outcome Measure Information:
Title
Primary end point of the study is the average pain level (scale 0-10) in the area of surgery during movement (walking a fixed number of steps) under active epidural analgesia, at the third day following laparoscopic colon or rectal surgery.
Description
To demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement at the third day after laparoscopic colon or rectal surgery in the fast-track design.
Time Frame
Third postoperative day
Secondary Outcome Measure Information:
Title
Post-operative pain level during movement in the first 2 days after laparoscopic colon or rectal surgery.
Time Frame
In the first 2 days after laparoscopic colon or rectal surgery
Title
Post-operative pain level during rest in the first 2 days after laparoscopic colon or rectal surgery.
Time Frame
In the first 2 days after laparoscopic colon or rectal surgery
Title
Post-operative pain level during rest and movement from the third (one day after epidural catheter removal) until the fifth day after laparoscopic colon or rectal surgery
Time Frame
In the first three days after epidural catheter removal
Title
Incidence of pain events and the average pain intensity in body parts outside of the area of operations.
Time Frame
In the first three days after epidural catheter removal
Title
Incidence of new organ dysfunctions
Description
Organ dysfunctions (cardiovascular, gastrointestinal, renal, respiratory, cognitive, infective)
Time Frame
In the first nine days after laparoscopic colon or rectal surgery
Title
Postoperative LOS
Time Frame
Period of hospital stay, an exspected average of seven days
Title
Patients level of satisfaction
Time Frame
In the first five days after laparoscopic colon or rectal surgery
Title
Incidence of side effects
Description
Side effects by IMP
Time Frame
In the first nine days after laparoscopic colon or rectal surgery
Title
Postoperative intensive care unit stay
Time Frame
Period of intensive care unit stay, an exspected average of one day
Title
Amount and frequency of intake of rescue medication
Time Frame
In the first five days after laparoscopic colon or rectal surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: aged 18 or over written informed consent no inclusion in other medical studies according to the AMG (German drug law) during the study period realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter Exclusion Criteria: ASA status IV-V allergy against etoricoxib, other components or other NSAID coronary heart disease heart insufficiency NYHA II-IV cerebrovascular disease peripheral arterial occlusive disease untreated arterial hypertonus active peptic ulcera or active gastrointestinal bleeding minor to severe liver dysfunction (beginning from Child - Plugh - Classification A) kidney insufficiency inflammatory bowel disease pregnancy (positive hCG laboratory test) or lactation Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index < 1 during study participation and for at least 3 consecutive months after study inclusion. placement in an institution on order of an official authority missing consent for saving and passing on pseudonymous data hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption no correct epidural catheter placement within 48 h after surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudia Spies, MD, Prof.
Organizational Affiliation
Dept. of Anesthesiology and Intensive Care, Charité, Universitätsmedizin Berlin
Official's Role
Study Director
Facility Information:
Facility Name
St. Hedwig Kliniken Berlin GmbH, Department of Anesthesiology and Intensive Care Medicine
City
Berlin
ZIP/Postal Code
10115
Country
Germany
Facility Name
Department of Anesthesiology, Sana-Klinikum Lichtenberg, Oskar-Ziethen-Krankenhaus
City
Berlin
ZIP/Postal Code
10365
Country
Germany
Facility Name
Department of Anesthesiology and Intensive Care Medicine, Campus Virchow Klinikum/Campus Charité Mitte, Charité Universitätsmedizin
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Facility Name
Department of Anesthesiology, Johannes Wesling Klinikum Minden Mühlenkreiskliniken (AöR)
City
Minden
ZIP/Postal Code
32429
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

We'll reach out to this number within 24 hrs